Impact of randomized antiretroviral therapy initiation on glucose metabolism

Objective:Prior studies have found that early HIV protease inhibitors contribute to glucose dysregulation. Few randomized trials have evaluated glucose indices in antiretroviral-naive individuals on newer antiretroviral therapy (ART). Methods:A5224s was a substudy of A5202, a prospective trial of 1857 ART-naive participants randomized to blinded abacavir-lamivudine (ABC/3TC) or tenofovir DF-emtricitabine (TDF/FTC) with open-label efavirenz (EFV) or atazanavir-ritonavir (ATV/r). Analyses used two-sample t-tests, Spearman correlation coefficients and linear regression. Results:A5224s included 269 nondiabetic individuals: 85% men, 47% white non-Hispanic, baseline median age 38 years, HIV-1 RNA 4.6 log10 copies/ml and CD4+ cell count 233 cells/&mgr;l. Overall, significant 96-week increases occurred in fasting glucose, insulin and the homeostatic model assessment of insulin resistance (HOMA-IR), P ⩽ 0.004. Assignment to EFV (versus ATV/r) resulted in significantly greater glucose increase [mean difference 4.4; 95% confidence interval (CI) 1.3, 7.5 mg/dl; P = 0.006] but not insulin or HOMA-IR (P ≥ 0.72). Glucose indices were not significantly different between ABC/3TC and TDF/FTC arms, P ≥ 0.18. Significant correlations were detected between changes in glucose indices and changes in BMI; all r ≥ 0.23, P ⩽ 0.001. In multivariable analyses, in addition to the EFV effect, higher baseline HIV-1 RNA and greater BMI change were significant independent factors associated with greater glucose increase. Conclusion:Changes in glucose metabolism were not significantly different between TDF/FTC and ABC/3TC-based regimens. A small but significantly greater increase in glucose was observed in those assigned to EFV. As glucose dysregulation may increase with time on ART, longer term studies will be needed to further clarify the clinical significance of these findings.

[1]  P. Sax,et al.  Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density , 2013, AIDS.

[2]  M. Di Nicola,et al.  Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy , 2013, Journal of medical virology.

[3]  C. Stehouwer,et al.  Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. , 2013, The Netherlands journal of medicine.

[4]  R. Haubrich,et al.  Metabolic Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected Individuals , 2012, Journal of acquired immune deficiency syndromes.

[5]  P. Sax,et al.  Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. , 2012, AIDS research and human retroviruses.

[6]  P. Sax,et al.  Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir , 2012, AIDS.

[7]  C. Katlama,et al.  Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment , 2012, AIDS.

[8]  D. Katzenstein,et al.  Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. , 2011, The Journal of infectious diseases.

[9]  R. Kuchenbecker,et al.  Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. , 2011, Annals of internal medicine.

[10]  E. Lambert,et al.  Effect of Nonnucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy on Dysglycemia and Insulin Sensitivity in South African HIV-Infected Patients , 2011, Journal of acquired immune deficiency syndromes.

[11]  P. Sax,et al.  Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  P. Sax,et al.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. , 2011, The Journal of infectious diseases.

[13]  D. Katzenstein,et al.  Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 , 2011, Annals of Internal Medicine.

[14]  A. Lazzarin,et al.  Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses , 2010, Journal of acquired immune deficiency syndromes.

[15]  R. Bosch,et al.  Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy , 2010, Diabetes Care.

[16]  L. Eberly,et al.  Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic , 2010, PloS one.

[17]  Lynne Peeples,et al.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.

[18]  G. Guaraldi,et al.  Detectable HIV Viral Load Is Associated With Metabolic Syndrome , 2009, Journal of acquired immune deficiency syndromes.

[19]  K. Samaras.  Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. , 2009, Journal of acquired immune deficiency syndromes.

[20]  A. Ganesan,et al.  Obesity among patients with HIV: the latest epidemic. , 2008, AIDS patient care and STDs.

[21]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[22]  P. Tebas.  Insulin Resistance and Diabetes Mellitus Associated With Antiretroviral Use in HIV-Infected Patients: Pathogenesis, Prevention, and Treatment Options , 2008, Journal of acquired immune deficiency syndromes.

[23]  Nina Friis-Møller,et al.  Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients , 2008, Diabetes Care.

[24]  J. Polak,et al.  Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  K. Tashima,et al.  Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095) , 2007, Journal of acquired immune deficiency syndromes.

[26]  D. Spiegelman,et al.  Incidence of Metabolic Syndrome in a Cohort of HIV-Infected Adults and Prevalence Relative to the US Population (National Health and Nutrition Examination Survey) , 2006, Journal of acquired immune deficiency syndromes.

[27]  M. Noor,et al.  Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  R. Shafer,et al.  Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides , 2005, AIDS.

[29]  Jeffrey N. Martin,et al.  The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Stephen R Cole,et al.  Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. , 2005, Archives of internal medicine.

[31]  R. Parker,et al.  The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults , 2004, AIDS.

[32]  J. Gatell,et al.  Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV , 2004, Journal of acquired immune deficiency syndromes.

[33]  R. Greenblatt,et al.  Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV‐Infected Women , 2003, Journal of acquired immune deficiency syndromes.

[34]  M. Serrano-Ríos,et al.  Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  M. Schambelan,et al.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.

[36]  W. Rozenbaum,et al.  Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance , 2002, The Lancet.

[37]  M. Schambelan,et al.  Metabolic effects of indinavir in healthy HIV-seronegative men , 2001, AIDS.

[38]  J. Fuller,et al.  Abacavir and diabetes. , 2001, The New England journal of medicine.

[39]  M. Dubé.  Disorders of glucose metabolism in patients infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[41]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[42]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[43]  P. Sax,et al.  Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz : ACTG Study A 5224 s , 2011 .

[44]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.